Novel Solvent-Free Excipients for Enhanced Drug Solubility and Delivery

Important results from the project

Yes, all initial goals were achieved. Production was successfully scaled from 0.3g to 3kg batches, in vitro release studies completed, and techno-economic calculations finalized. Additional important results include: novel formulations for both lipophilic and hydrophilic drugs (cyclosporine, ibuprofen, aspartame), new analytical methods (SAXS, HPLC, GC-MS), and strengthened collaboration between Emulsi Biotech AB and RISE. The results supported acceptance into Smile Venture Hub incubator.

Expected long term effects

The project´s long-term effects include establishing a scalable NanoLIPID platform technology capable of formulating diverse drug types - from small molecules to peptides and proteins. Novel formulation methods discovered will enable new patent families and market expansion across multiple pharmaceutical sectors. Results de-risked the company for investors, facilitating future funding for extensive in vivo studies required for market entry.

Approach and implementation

The project was structured into three work packages with clear objectives and timelines which were followed effectively. WP1 focused on production scale-up, successfully upgrading from 0.3g to 3kg batches using a new rotating bed reactor. WP2 investigated techno-economic evaluation and environmental impact, integrating scale-up data with supplier agreements and material pricing. WP3 conducted in vitro studies, testing drug incorporation and release using novel analytical methods.